In Brief: Astra Merck Prilosec
This article was originally published in The Tan Sheet
Executive Summary
Astra Merck Prilosec: Astra plans to file applications for effervescent formulation of the proton pump inhibitor omeprazole in European markets during the first quarter of 1999. Astra Merck maintains it has not yet determined plans for the effervescent formulation, nor has it selected an OTC dosage form. The effervescent tablet would be a logical option for the company to pursue in an OTC switch. The Jan. 26 issue of "The Tan Sheet" (p. 1) had reported the filing would be in the U.S...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning